Trial reportClinical pharmacology and therapeutics2025
A Pharmacometric Method for Quantitative Determination of Improvement in Body Composition and Characterization of the Exposure-Response Relationship during Treatment of Obesity with Tirzepatide.
Trial report in Clinical pharmacology and therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
About half of the world's population is living with overweight or obesity. Tirzepatide is an approved treatment for chronic weight management. We sought to characterize the exposure-response relationship for weight reduction in patients with overweight or obesity and quantify the associated changes in body composition. Monthly body weight measurements were available from 2,539 study participants in a phase 3 clinical trial investigating placebo, 5, 10, or 15 mg of tirzepatide administered once-weekly. The dependent variables used for modeling were fat-free mass (FFM) and fat mass. These FFM and fat mass values were calculated for each patient based on their total body weight, height, and sex. The exposure-response model revealed that administration of tirzepatide resulted in three times greater reduction of fat mass than that of FFM. This differential effect resulted in improved body composition over time. The model results showed good agreement with available data from a subset (10%) of clinical trial participants who had dual energy x-ray absorptiometry (DXA) measurements. For the same drug exposure, females achieved greater weight reduction than males. Study participants with higher baseline weight or body mass index at baseline had a slower rate of weight reduction and were expected to take longer to reach their nadir weight. We present and propose the use of a pharmacometric-based body composition model to describe weight reduction in future clinical trials investigating similar drugs in similar patient populations, in lieu of DXA scans. In such future trials, our approach can be used to describe exposure-response relationships, optimize doses, and investigate covariates, while considering potential differences in fat mass and FFM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.